Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients.

Episode Summary

Dr. Warrick Bishop, a practicing cardiologist and author, discusses PCSK9 inhibitors—a new class of cholesterol-lowering drugs. The episode explores how these monoclonal antibodies work at the molecular level, their clinical benefits compared to traditional statins, and their current availability in Australia, with particular focus on how high-risk patients can access them.

Key Takeaways:

• Statins remain the foundation of cholesterol management as they are effective, affordable, well-tolerated, and extensively studied over two decades.

• PCSK9 inhibitors are monoclonal antibodies that prevent the breakdown of LDL receptors, allowing them to be recycled and remove more bad cholesterol from the bloodstream.

• PCSK9 inhibitors can lower LDL cholesterol by 50-60% more than statins combined with ezetimibe in high-risk patients.

• The discovery of PCSK9's role in cholesterol management came through genetic research showing that people with low PCSK9 levels had better cardiovascular outcomes and longevity.

• Clinical trials (Fourier and Odyssey) have demonstrated mortality benefits with PCSK9 inhibitors, particularly in high-risk patient populations.

• In Australia, PCSK9 inhibitors are currently government-funded only for patients with familial hypercholesterolemia who meet specific criteria.

• Private patients unable to meet PBS criteria can self-fund PCSK9 inhibitors for approximately $1,500-$3,000 annually, with potential health fund contributions reducing out-of-pocket costs to around $100-150 per month.

• PCSK9 inhibitors are particularly valuable for patients who are intolerant or unresponsive to statins, ezetimibe, nicotinic acid, and other traditional cholesterol-lowering agents.

• These drugs also lower lipoprotein(a) levels, providing additional cardiovascular benefit for patients with elevated levels of this risk factor.